Takeda’s TAK-279 is being evaluated in a Phase IIb clinical trial to treat moderate-to-severe plaque psoriasis. Credit: Martin Trotter / Flickr (Creative Commons).

Takeda has reported positive data from a Phase IIb clinical trial of TAK-279 (NDI-034858) in moderate-to-severe plaque psoriasis patients.

The double-blind, randomised, multiple-dosed, multicentre, placebo-controlled Phase IIb trial has been designed for assessing TAK-279’s tolerability, efficacy, and safety in the indicated patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In the trial, 259 participants were randomised in a 1:1:1:1:1 ratio to receive either a 2mg, 5mg, 15mg, or 30mg dose of TAK-279 once-a-day or a placebo for 12 weeks.

According to the findings, 44% of the TAK-279 5mg cohort, 68% of the 15mg group, and 67% of the 30mg cohort achieved the trial’s primary endpoint of a Psoriasis Area and Severity Index (PASI) of 75 at 12 weeks.

At the 30mg dose of TAK-279, 46% of participants achieved PASI 90 and 33% achieved PASI 100 at 12 weeks.

The Physician Global Assessment (PGA) score of 0/1 was achieved by 27%, 49%, and 52% of the 5mg, 15mg, and 30mg treatment groups, respectively.

Takeda research and development president Andy Plump said: “These compelling TAK-279 data strengthen its potential for people with moderate-to-severe plaque psoriasis.

“The highly selective TYK2 inhibition seen with TAK-279 spares inhibition of other members of the Janus kinase (JAK) family, which we believe should avoid JAK-related toxicities.

“We are confident that we can execute a comprehensive development program and deliver a potential best-in-class therapy for patients, given Takeda’s strong background in immune-mediated diseases, including inflammatory bowel disease.”

The company expects to receive topline results from a Phase IIb trial in psoriatic arthritis and intends to commence a Phase III trial of TAK-279 in psoriasis in FY2023.

It also plans to assess TAK-279 in other immune-mediated diseases, including inflammatory bowel disease (IBD) and systemic lupus erythematosus (SLE), as well as other indications in the future.